In vivo silencing

IG Irene González-Recio
JS Jorge Simón
NG Naroa Goikoetxea-Usandizaga
MS Marina Serrano-Maciá
MM Maria Mercado-Gómez
RR Rubén Rodríguez-Agudo
SL Sofía Lachiondo-Ortega
CG Clàudia Gil-Pitarch
CF Carmen Fernández-Rodríguez
DC Donatello Castellana
ML Maria U. Latasa
LA Leticia Abecia
JA Juan Anguita
TD Teresa C. Delgado
PI Paula Iruzubieta
JC Javier Crespo
SH Serge Hardy
PP Petar D. Petrov
RJ Ramiro Jover
MA Matías A. Avila
CM César Martín
US Ute Schaeper
MT Michel L. Tremblay
JD James W. Dear
SM Steven Masson
MM Misti Vanette McCain
HR Helen L. Reeves
RA Raul J. Andrade
ML M. Isabel Lucena
DB Daniela Buccella
LM Luis Alfonso Martínez-Cruz
MM Maria L Martínez-Chantar
request Request a Protocol
ask Ask a question
Favorite

After 24 h of APAP treatment, mice were randomly divided into two experimental groups (n = 4), 27 μM of silenced Cnnm4 (siCnnm4) or unrelated siRNA control (siCtrl), (Custom Ambion® In Vivo siRNA, Cat#: 4457302) by intravenous tail injection using Invivofectamine 3.0 Reagent (Thermo Fisher Scientific). Mice were sacrificed at 48 h after APAP overdose.

Mice were also silenced employing Cnnm4 GalNAc siRNA molecule. Thus, after 24 h of APAP treatment, mice were randomly divided into two experimental groups (n = 4), GalNAc siCnnm4 or control GalNAc siRNA were administered by subcutaneous injection. Mice were sacrificed at 36 and 48 h after APAP overdose.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

0/150

tip Tips for asking effective questions

+ Description

Write a detailed description. Include all information that will help others answer your question including experimental processes, conditions, and relevant images.

post Post a Question
0 Q&A